Paxman AB (publ) (PAX.ST) Q3 2026 Earnings Call Transcript
Review management commentary and the analyst Q&A from Paxman AB (publ) (PAX.ST)'s Q3 2026 earnings call. Use the transcript to track changes in demand, guidance, operating priorities, and the KPIs behind the company's reported results.
Full transcript
5,661 words · about 29 min read
Maria Karlsson Osipova: Hello, everyone, and welcome to DNB Carnegie. My name is Maria, and I'm an analyst here at the bank. And today's topic of conversation is Paxman's report for the third quarter of this year. And with me here in the studio or well, not physically, but I still do have Richard Paxman here online. Hi, Rich.
Richard Paxman: Hi. Good to be here.
Maria Karlsson Osipova: Nice to have you here as well. The format this time is a little bit different, but still much the same. So we start off with the presentation by Rich that's going to take us through the quarter and the key developments in the quarter. And then we're moving on to a short Q&A session. I've gotten some questions on my e-mail that we're going to ask, but if you also feel like you have some questions that are still unanswered once we're done, you're very welcome to e-mail me them, and then the company will provide us a written Q&A by sometime next week. So yes, please, Rich, take it away.
Richard Paxman: Thanks so much, Maria. And as I said, great to be here again. A really strong quarter, really pleased with our performance and so much going on. I think many of you have probably seen our updated press releases. But group sales amounted to about SEK 103 million for the quarter, so well up on prior year's quarter from SEK 87 million, but a really strong quarter for EBITDA and profitability. So SEK 18.1 million compared to just under SEK 8 million for the quarter in 2025. That was a positive impact of around SEK 7 million from the Dignitana Group, but overall improved profitability, which we'll talk about shortly. Really happy with how the momentum with insurance-based billing still goes. I think some people may have thought we were going to expect a little dip in Q3 based on a strong Q2, but actually, that momentum is still there, and the outlook looks really strong. So achieving revenues in the U.S. of about SEK 67.8 million, which is about $7 million compared to SEK 52 million in the prior year. October was a great month. We secured our first order for our neuropathy systems with a really well-known global cancer hospital group and hopefully, many more to come with them when we get those installed in December. You'll see the new branding in our report, which hopefully you all love, but we announced the official launch of our neuropathy system in November, but also that move to move beyond scalp cooling for the group, which is really exciting, that evolution to now what we call the Paxman Group. Perfectly timed came the publication of the neuropathy data from Singapore in a really well-known journal through ASCO, which is the JCO, with excellent results. And then a really significant update from a regulatory perspective. We're now in that substantive review phase, and we'll touch on that very shortly in terms of time lines. We're keeping up with these key performance indicators, which hopefully you like, which really details the split between insurance-based billing versus self-pay. Again, we're seeing 27% growth in our U.S. revenues year-on-year for the quarter and over 100% growth in insurance-based billing, which is great for Paxman. Looking at Dignitana, the results on a percentage basis look a little bit disappointing. But in reality, they're relatively flat, but more work to come in terms of getting those sites to switch over to insurance-based billing in the coming months. It's important to remember that Paxman had a head start there. From a Rest of World revenues perspective, again, it looks relatively flat, but I think it's really important to explain our Rest of World revenues are U.K., which is a very established market versus our distributors in some direct markets like France, Germany, Spain, et cetera. If you separate the U.K., which is the established market and it's just replacement and it's not really the sort of future of our business in terms of growth, that actually declined this year, which was expected because of the capital rollout expected in that market versus a 17% growth in those other markets. So actually, the underlying growth for the rest of the world is still strong, and we're confident that we will continue to grow. Gross margins for the quarter have been affected somewhat, so a bit weaker, but we are still confident we'll find ways to improve gross margins over time. There may be a little bit of inflationary pressure there, which will resolve into the new year with price increases. But also we had some crossover with service providers where there were some extra costs sat in that area. And I've talked about how we're going to improve U.S. margin going forward. EBITDA margin is looking really strong this quarter at 17.5% and adjusted it to nearly 20% once we take out those CIPN costs. So overall, we're really pleased with our performance. From a cash flow perspective, we've seen a reasonably strong cash outflow. Again, that's investments into what we're doing. But it's also important to see that based on increased activities over the last 2 quarters, we've got a higher debtor book, especially with the change in business model where we used to get cash in immediately in the U.S. from our customers. And now that takes a little bit longer because we're working through distribution channels. But all in all, really strong position to take us through into 2027. I've touched on these results really. This gives you a sort of nice visual. There is that slight dip, but actually that overall profitability improving, and we're going to continue to see and drive those EBITDA margins. Quick update on acquisition. As we work towards restructuring the group and making sure that it was working appropriately, we're still seeing a reduction in personnel and operating costs for the group. We expect that now to plateau in reality as we've done most of the integration activities, and there's really no effect on overall profitability now. But what it does show is that the acquisition was a really good move and what it really is showing is improved profitability for the group. Now we've got a great group structure. So U.S. focus, it has to be a U.S. focus, of course, 60% of our revenues are coming from this market in particular. And we're seeing strong installed base. It's important to remember, it takes a bit of time for those installs to come through and start really driving sales. We manufacture, we deliver, we install, then we train and then we get the customer onboarded. So it does take a little bit of time. And so it doesn't always convert to immediate sales when we have those installations there. You're seeing that increase in caps sold through IBBM for Paxman. We've seen a slight dip in self-pay, which is expected as customers transition from one model to the other. And as I mentioned on Dignitana, relatively flat changes at the moment, which is expected. We're not driving new customer installs for that business. Looking at utilization. Again, very similar trends to the prior quarter, which is good. There's very clear indication that when a site switches, we see much better utilization, which is important, and that trend does continue. They're slightly weaker than the prior quarter. But in reality, we've installed more systems. And again, it takes a little bit of time for those sites to get up and onboarded and running. But overall, very confident still in this approach. We'll continue to track these trends. But I think we've got to be careful on reading too much into small changes from quarter-to-quarter. But the trend is positive, and we'll continue to work on how we improve that overall utilization. Coverage still looks good in the U.S. market from our Hub Services. And hopefully, we can continue to work on improving that positive coverage for patients. This is one of the key areas that will help that coverage, and that is the legislation piece that's happening around the country. So as we know, New York and Louisiana are already -- have effective bills or laws that are mandating scalp cooling coverage. And then in January 2027, we've got Maryland, West Virginia, Connecticut and California all coming on board. This is really helping drive the switch and patient awareness. Maryland is also showing an active increase in not only people transitioning before or at the start of January 2027, but more sites coming on board, and you'll see that from the order book when I talk about that shortly, but very, very positive where sites that are not scalp cooling realize that it's something that they have to do, and they're now ordering equipment from us. Same in California, very exciting, and we've already seen some of that momentum in Connecticut. There's 25 other states already active with advocacy, looking at getting those on the agenda over the next 2027 legislative sort of outlook, which is great. Just as a reminder, this is what happens when we do get this utilization piece right. Our current rate for Q3 was $6.8 million. That's annualized at $27 million on an annual basis. If you then look at saying, right, okay, let's use those utilization figures, let's move all customers on to our insurance-based billing. That conversion opportunity lends us a $47.2 million revenue just by switching. Then if we add and look at our additional order book, and apologies, this slide is slightly out of date. We need to update the order book. But at 78 systems, that's $2 million the 135 systems we've got on board, that's over $3 million additional revenue based on utilization figures. So 3 key strategic priorities we need in the U.S. that's conversion, new customer acquisition and driving utilization beyond our current IBBM, which is about education, awareness and stronger coverage and payment with the payers. Rest of World, as I said before, don't be disappointed with the rest of world sort of what it looks like when it includes the U.K. We look at South America, Oceania, Europe, Asia, and you look at the figures there that are actually improving over time, where the U.K. has declined a little bit, which is expected based on the fact that, that is a relatively saturated market, and we're just replacing capital now over time. But the other markets are delivering a 17% growth to date, which I think is very positive. As I said, the order book stands at 238 systems, of which 135 are for the U.S. market, which is very exciting and really shows that this improved demand. And it's a real mixture of some additional systems for locations, but actually, there's a lot of new orders for insurance-based billing locations that are out of our current mix. And on to CIPN. So let's remember why -- what the benefits are of delivering this technology to our existing customer base, absolutely patient value and such an unmet need, which is, in many cases, even considered beyond what we're doing with chemotherapy-induced alopecia. But there's such synergistic value in delivering our neuropathy systems. We worked for 30 years developing this amazing network, this supply chain and distribution and this infrastructure that we've set up. We've been working for years with some of the best cancer centers in the world. So we've got thousands of potential customers that we're already working with, which typically would take a long time to build relationships. We're talking to the same physicians, the same clinical teams and ultimately, in many cases, the same patients. This gives us a real strategic advantage to speed up the process that we did with scalp cooling, meaning faster adoption, lower commercial risk for us as an organization, better customer value and importantly, that expanded patient impact, which is incredibly exciting. And that ultimately will lead to increased revenues per cancer center for us and really enjoying those economies of scale, especially in people and infrastructure. Just a quick reminder on how we'll be working. So in the U.K., France and Spain, we'll be working directly selling capital equipment and accessories, meaning the gloves and the boots on an annual basis, so they'll be reusable. That will be the same with our distributors, primarily focused in Australia, Germany, Italy, Singapore and the Netherlands to start with, and then we'll expand beyond that in time. But focus is really important for us this time with CIPN. And then for our U.S. business model, we're going to install the capital at a lower lease cost, about $300 per system we're estimating. We're going to sell the accessories, so the kits, the gloves and the boots at circa $2,000 to $3,000 per kit, so a higher price point than our current scalp cooling equipment. Our plan is a capital rollout of about 150 systems in that first 2027 to 2028, but we have the capacity to do more if we need to, but that will be our minimum, and there's already a huge amount of interest. And just remember, we've already started on the insurance process. So we've got the CPT III codes already established, and the plan will be to accelerate the CPT I coding and really sort of navigate the pathway much quicker than we ever did with scalp cooling from a reimbursement perspective. Our launch time line, we've already done the V1 build. Those V1 systems are pilot systems already installed in the U.K. hospitals, private hospitals, we'll be getting feedback soon. Europe has signed contracts and we'll start very soon in France and Germany and other markets. And then we've got some other clinical trials planned in the U.S. We've done our V2 launch and our new branding, which was amazing, fantastic day, very proud moment for us. And then now we're building our V2 systems, so our commercially ready systems. The plan is to rebuild between 100 and 150 systems until the end of the year in one of our facilities. There will be an audit on our facility in December to sign off that build, and then we will be able to sell those systems starting in sort of mid-December, hopefully, early December, if all goes well. As you know, we've got our first order, which is exciting, and we hope to have many more before we can actually sell also. Expected FDA clearance will happen in Q2 2027. You'll have seen the FDA announcement. Our actual end date is March 2027, but there is a lot strong likelihood that we will have additional time or additional time yet for additional information requests from the FDA. Just a reminder on our strategic priorities. Simple Switch was #1, which we've done a really good job, but we need to still increase the momentum, but I think that's happening. Product commercialization, we've achieved that. Revenue growth, we're definitely achieving that, but more to come. Operational excellence has been a really key point for us this year with what we call our model office rollout, really improving efficiencies, and that's gone live at our new offices and then clinical excellence. Hopefully, you can see that running through what we're doing. Take a look at our new website and our clinical data brochures, but also the recent publications of what we're doing, really exciting. So thank you very much, and I look forward to some questions, Maria.
Maria Karlsson Osipova: Thank you very much. Let's see. So I've gotten some here by e-mail, and I've also written down some questions here as well. And of course, we start with the most interesting topic to most investors if we only judge by the amount of questions, and that's IBBM. So could you say anything more maybe about the split between new IBBM sites and ones switching? And how has that developed in Q3?
Richard Paxman: Yes. So the actual -- the switch in Q3, I think it was weighted towards more new locations as opposed to actually switching sites. But what we're starting to see now is again an uptick in transitioning sites. So it's strange. It sort of goes in peaks and flows. And I think that legislation piece is helping. From an order book perspective, though, if you look at that 135 systems, a lot of those are new locations for us. They may be part of groups like Kaiser Permanente who are moving all their locations on to insurance-based billing and also people like the Maryland Group where they want to expand and then switch the model as well based on legislation. So it still is a mix, but we seem to be weighted to a degree with new locations at the moment.
Maria Karlsson Osipova: All right. And I usually ask this question every quarter on an update on the obstacles that you may be facing and the obstacles to converting from self-pay to IBBM. Any update there in Q3? Anything new you're seeing out there?
Richard Paxman: Not seeing any more obstacles. I think the obstacles are becoming less, and I think the confidence is increasing. So I think now the biggest obstacle has moved from sort of lack of clarity or uncertainty over coverage and payment, but now more about where does it fit as a priority as a cancer center. We've got 5 of the key projects that we need to deliver, where does scalp cooling fit. So I think that is our biggest issue now. But as you can start -- you will start to see and you are already seeing, there is that momentum there, which is good. And I think 2027 we'll see that speed up even more especially in the community.
Maria Karlsson Osipova: Yes. Now that you've mentioned community and also these big oncology actors and networks, we have previously talked about some large ones, and we also talked about NYU and Yale and the OneOncology also. So the start-up there has been pretty slow. Have you learned anything from those processes? Are you taking anything away to maybe speed it up when the next big actor comes into play?
Richard Paxman: Yes. I mean we try and learn as much as we possibly can from each of these providers, especially the large academic providers. But there's so many differences in the way they operate that you can take as much as you possibly can and you can teach best practice. And what we do most of the time is connect them so they can have real peer-to-peer conversations. But they -- many of them use different systems, different processes. So we support as much as we can, and we do learn and we share that knowledge, but it doesn't -- there's no quick fix, unfortunately. What I think helps when you look at the aggregators as such like OneOncology, like U.S. Oncology, they have some central shared services. So perhaps there will be some economies or synergies in the ability to be able to set up centralized revenue cycle management, for example. So that could help overall. But the aggregators are key for us now. So we've done well with some of the large academic sites. There's still some that are dragging their feet, let's say, but we really need to push these oncology group -- community oncology groups now. So I'm out here in America at the moment, and we've been with U.S. Oncology this week in Las Vegas. And last week was with OneOncology in Nashville. So yes, we're confident there's momentum there. And I think, again, 2027 is going to be -- see some changes, which is exciting.
Maria Karlsson Osipova: Yes. And just staying a little bit on the aggregator topic there. One question that I've gotten on the e-mail was, how is the aggregator model affecting gross margins or average pricing? Now that these sites are starting to come more and more on, are you seeing any effects?
Richard Paxman: Yes, very good question. I think it's early days at the moment to see a real shift in pricing because there's not enough of them to wait a reduction in pricing, but we did talk about some pricing pressure with some of the community oncologist based on a lower payment rate for community oncology providers. So you might start to see that into the new year as we adopt more sites. But I think if we take a step back and say, yes, there may be some price pressure, but volume should, I say, should rather than will increase based on our historic sort of trends with the switch. So lower price point potentially, but a higher volume.
Maria Karlsson Osipova: All right. And a little bit on the order book. So 238 you have an order book right now, of which over 100 for U.S. you mentioned in your presentation. Is there anything you can split more on the geographic split and maybe some timing details you can share with us and maybe visibility?
Richard Paxman: Yes. Okay. So I'd be lying to you if I said I could give you the split for rest of world because they don't come in chunky orders. There'll be some for Australia, Italy, the Netherlands. India is actually performing beautifully at the moment, which is great, and we'd hoped it had to. We've got the right partner at the moment, the right infrastructure set up there. But from a U.S. perspective, I think I touched on it, there's some large sort of IDNs that are -- integrated delivery networks that are taking on board additional equipment as they see the legislation happening. From a timing perspective, we'll get a chunk out in Q4, but then Q1 should see the remainder of those systems installed. U.S. may stretch into Q2 just because we only allocate a certain amount, but I'm working with our ops team at the moment to see what we can do. The faster we get them installed, the faster they start providing a return on investment. So we're reviewing it. But we were excited with the 80 systems on order last quarter. This is really building, which is great.
Maria Karlsson Osipova: Yes, indeed, great numbers to see. So how should we think about the IBBM ramp from here on now? Do you think you can keep the same pace?
Richard Paxman: Yes, I think we can because there's a -- like I said, it's getting these community oncology providers on. So if we can do those, that creates the volume of sites, if that makes sense. The legislation is pushing certain states, the pressure on other locations now to move. So we feel this is probably the most confident we felt through this process, apart from right at the beginning, where we're like, yes, these sites are going to be all switching. It's a no-brainer. But no, we feel much more confident there.
Maria Karlsson Osipova: All right. And so next, I'd like to zoom out from the U.S. and look at the rest of the world. You did mention that U.K. is a bit of an established market now, but you still see growth in rest of the world. But if you can elaborate a bit more on that. So where do you see the growth coming from?
Richard Paxman: So we've had some good growth in Europe this year. So we've had -- France has been a really good market for us. Spain has been a good market for us. But we've limited investment when I talk -- we go direct in those markets, and we have one person in each of those markets, but they're delivering growth, which is great. India is looking very strong. Japan is a good market, but we're not seeing as much growth as we'd like, but they've been impacted a little bit by foreign exchange and price sensitivity. So we're helping them and supporting them at the moment. Australia continues to be a good market. The Middle East is a little hit, hit, miss at the moment, but I think longer term, has some interest. What I'm excited about is when we get the neuropathy product up and running in those markets. And I think that's going to allow us to have more success, I think, with sites and places where perhaps they've been a bit hesitant about installing scalp cooling a bit like the Swedish, but then see the importance of the neuropathy based on the health impact. And then longer term, give them confidence in what we are doing, who we are and then get scalp cooling installed as well. So a really synergistic value again on growth for our rest of world markets. But 17% growth is still strong, and I'm really pleased with that. And I think we can do so much more with the right investment longer term, but we put limited in.
Maria Karlsson Osipova: Yes. And thank you for a very great segue into the CIPN, the neuropathy product here because my next question is actually on that and more specifically on the FDA process. So can you share with us your thoughts on the downside scenario? Say, the FDA do require more clinical data. What is the fallback for you there?
Richard Paxman: Yes. Okay. So I would have said I'm 100% confident in the Singapore data beforehand, but I was 100% confident in the FDA application. So I'm going to refrain from saying that. But I am confident in the Singapore data. It's just been published in the JCO. It's good, strong data. And medical devices typically, I don't need data historically, most changed very recently or randomized controlled data has not always been as a most like a pharma trial, although I think it's the right way to go in the right science. So if there is an issue and the FDA think, well, actually, we'd like an RCT. As you know, we've got the Dana-Farber trial, which is -- it's recruited over 30 patients now. The primary endpoint can be met at around 50 patients, maybe just a bit more. And we expect to have a data readout by -- a published data readout in a poster presentation early in the new year, but we can do some interim analysis if we need to, to support any questions from the FDA. So whilst being confident, we have backup plans to support if we don't get what we need. I would be very surprised if they wanted the SWOG data. I mean that's got 700 patients in it, by the way, now, which is pretty impressive. That would be a big ask for what's technically a very safe device, but we'll see. I think I mentioned previously the issues around the questions early on were more about safety than efficacy. We've got some good safety endpoints to share anyway. So we'll keep everyone updated on where we're at, but we're feeling confident and we've got a good submission in.
Maria Karlsson Osipova: All right. And another short follow-up. When would you expect the SWOG data to be published because that's a long study.
Richard Paxman: Yes, it's a big study as well. So we've got another 75 patients to go or something like that. So I think that will complete maybe March next year, possibly sooner depending on what happens over the holiday period. Then you have to wait 12 weeks after for your last patient. So that's bringing you another 3 months or maybe June. So I think by the end of 2027, it sounds a long way away, but it'll be here before we know it, we'll have some really good data in addition to the good data we've already got.
Maria Karlsson Osipova: Yes. All right. And since we are already live in Europe or we are -- you are already live with the product in Europe, how does this soft launch affect revenue recognition? We've touched upon this in the previous quarter. So should we expect some revenue dropping into the top line already in Q4?
Richard Paxman: You will have a little bit of revenue in Q4, and then you'll expect to see it properly hitting into 2027.
Maria Karlsson Osipova: And another investor question is also on the -- you touched upon this in the presentation. So basically, your idea in your picture is that the launch will -- the launch trajectory will not be as slow in quotation marks as it was for scalp cooling for the CIPN product. Could you elaborate more on that? Why do you think that is so?
Richard Paxman: Yes, good question. So it's back to that synergistic value and the work we've already done in over the last years. So if you think about scalp cooling, every new cancer center has been finding a new relationship, finding a contact. And that takes time building relationships, doesn't it? As today, we have over, I think, 3,000 cancer centers using our equipment. In the U.S. alone, we have 1,000 cancer centers. I can call up many of those doctors don't worry, I won't personally be doing it. But I mean, you have a foot in the door already. So that adds a lot of speed. We've learned so much on the reimbursement pathway in the U.S. market. So again, that speed, that understanding of what to do and how to do it is there in our team already the experience, and we've got much more resource than we ever did have. But then you go back to the clinical side. CIPN has been a problem that cancer patients have faced for many, many years with no opportunity to treat. The only way we can help patients at the moment is reducing chemotherapy, and that's not good for a patient. So the clinical need, the buy-in from physicians, the buy-in from the nursing teams is very different. It was funny, I was at Nevada Cancer Centers yesterday and speaking to the doctor and she's doing great and she loves scalp cooling and she's really pushing it across their cancer centers. But she was like, when are you doing something with hands and feet. And I mean it's a question every doctor you meet asks, and they're so enthusiastic about it. So again, that I think I've answered the question.
Maria Karlsson Osipova: A bit on the cost side then. You have mentioned before that SEK 20 million is an approximate sum that you would expect for the year on the CIPN costs. Does that picture still hold?
Richard Paxman: Yes, I think so. It's not far off. You've got roughly the SEK 10 million of the capital rollout plus then the additional sort of costs with building the infrastructure and marketing. So yes, give or take, maybe a bit more if we're a bit more aggressive at the back end of next year, the rollout could be stronger than we expected. So we might want to speed things up a little bit. But overall, yes, the SEK 20 million feels comfortable at the moment.
Maria Karlsson Osipova: Yes. And in general, on costs, you mentioned that there are not that much more Dignitana savings to -- mostly to take out, but how should we think about generally cost development going forward?
Richard Paxman: Yes. So you've seen a slight change in the trend this quarter. So the prior quarters were some heavy investment into regulatory into still product development. I mean the brand relaunch, as you could see, has been significant and a significant investment. So some of those costs are now starting to reduce. We have got the increased headcount, of course. So you've got to remember those aren't going, but the one-off costs have reduced substantially. So moving forward, you'll start to see increasing costs in personnel to deliver on our goals, but those should be matched by revenues, if that makes sense. So whereas we've seen increased CIPN costs, but without a return on investment as such as yet, into the new year, you'll see a trend in increased head count, some operating costs, but yes, they'll have normalized a little bit now, not as scary.
Maria Karlsson Osipova: All right. And in the interest of time, I thought that we're going to maybe wrap this up a little bit. And we're a little bit into Q4 now. And I know that you never guide or so, but could you paint us a broad picture? What do you see ahead going forward going into '27? And are you happy with how Q4 has started so far?
Richard Paxman: Yes. So I'm pleased with where we're at and how it started in terms of that momentum. You've seen the order book. So I think that's a good signal, and we're already -- I've shared that with everyone. So that says right, okay, we're going in the right direction. It's too early days yet to see exactly where we're at from utilization, et cetera, but the trend feels like it's appropriate. What I'm more excited about is that 2027 piece, there's further legislation coming into play, the big shift in further IBBM sites, lots of demand from everywhere. And then ultimately, that real launch of the neuropathy into U.K. and Europe and starting to see some sales there. And then midway through 2027, being prepared for the rollout for CIPN is something that we must all focus on, which will be -- I mean, it's going to be -- it will be a big year next year.
Maria Karlsson Osipova: All right. Thank you very much, Rich, for taking the time and talking to us about your Q3.
Richard Paxman: Pleasure. Great to be here. Thank you.
What will you track for PAX.ST after the call?
Use management commentary to frame your research, then explore TickerTrends coverage for demand signals and company KPIs between earnings releases. Available metrics vary by company.
- Find available KPI forecasts and demand trackers
- Discuss coverage and workflow needs with our team
Continue your research
Browse more PAX.ST calls to compare quarters, or search for another company below.